Literature DB >> 36035557

Medications for Opioid Use Disorder Do Help Patients.

Kim-Long Nguyen1, Jessica Forbriger1, Arthur Forbriger1, Evan S Schwarz1.   

Abstract

Much of the focus on the current opioid crisis remains on how we arrived here and who is to blame. Despite having effective treatments for the management of patients with opioid use disorder (OUD), rates of overdose deaths continue to increase. As such, the focus needs to shift to increasing access to medications for OUD and better incorporation of harm reduction strategies to decrease not just the mortality but also the morbidity associated with OUD and other substance use disorders. Unfortunately, significant barriers rooted in misunderstanding and bias still limit access and prevent patients with OUD from seeking and staying in treatment. Until these are overcome and medical practice changes, both physicians and patients will continue to struggle to overcome this problem. Copyright 2022 by the Missouri State Medical Association.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 36035557      PMCID: PMC9324703     

Source DB:  PubMed          Journal:  Mo Med        ISSN: 0026-6620


  26 in total

1.  Reduced injection frequency and increased entry and retention in drug treatment associated with needle-exchange participation in Seattle drug injectors.

Authors:  H Hagan; J P McGough; H Thiede; S Hopkins; J Duchin; E R Alexander
Journal:  J Subst Abuse Treat       Date:  2000-10

2.  Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence.

Authors:  David A Fiellin; Michael V Pantalon; Marek C Chawarski; Brent A Moore; Lynn E Sullivan; Patrick G O'Connor; Richard S Schottenfeld
Journal:  N Engl J Med       Date:  2006-07-27       Impact factor: 91.245

3.  Emergency Department-Initiated Buprenorphine for Opioid Dependence with Continuation in Primary Care: Outcomes During and After Intervention.

Authors:  Gail D'Onofrio; Marek C Chawarski; Patrick G O'Connor; Michael V Pantalon; Susan H Busch; Patricia H Owens; Kathryn Hawk; Steven L Bernstein; David A Fiellin
Journal:  J Gen Intern Med       Date:  2017-02-13       Impact factor: 5.128

4.  Why aren't physicians prescribing more buprenorphine?

Authors:  Andrew S Huhn; Kelly E Dunn
Journal:  J Subst Abuse Treat       Date:  2017-04-12

Review 5.  The role of needle exchange programs in HIV prevention.

Authors:  D Vlahov; B Junge
Journal:  Public Health Rep       Date:  1998-06       Impact factor: 2.792

6.  French field experience with buprenorphine.

Authors:  Marc Auriacombe; Mélina Fatséas; Jacques Dubernet; Jean-Pierre Daulouède; Jean Tignol
Journal:  Am J Addict       Date:  2004

7.  Trends in Buprenorphine Treatment in the United States, 2009-2018.

Authors:  Mark Olfson; Victoria Shu Zhang; Michael Schoenbaum; Marissa King
Journal:  JAMA       Date:  2020-01-21       Impact factor: 56.272

8.  Postincarceration Fatal Overdoses After Implementing Medications for Addiction Treatment in a Statewide Correctional System.

Authors:  Traci C Green; Jennifer Clarke; Lauren Brinkley-Rubinstein; Brandon D L Marshall; Nicole Alexander-Scott; Rebecca Boss; Josiah D Rich
Journal:  JAMA Psychiatry       Date:  2018-04-01       Impact factor: 25.911

9.  Trends and Geographic Patterns in Drug and Synthetic Opioid Overdose Deaths - United States, 2013-2019.

Authors:  Christine L Mattson; Lauren J Tanz; Kelly Quinn; Mbabazi Kariisa; Priyam Patel; Nicole L Davis
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2021-02-12       Impact factor: 17.586

Review 10.  Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria.

Authors:  Rebecca McDonald; John Strang
Journal:  Addiction       Date:  2016-03-30       Impact factor: 6.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.